ZIOP Insider Trading Activity and SEC Form 4 Filings
ZIOP insider trading summary
No open-market insider purchases or sales of Ziopharm Oncology Inc (ZIOP) have been reported on SEC Form 4 in the past 12 months.
Latest ZIOP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 22, 2021 | Groot Eleanor De | EVP, Operations | Sell | $26K (20,132 @ $1.27) |
| Nov 17, 2021 | Kevin S. Boyle Sr. | Chief Executive Officer | Buy | $13K (9,116 @ $1.40) |
| Nov 16, 2021 | Kevin S. Boyle Sr. | Chief Executive Officer | Buy | $1K (884 @ $1.40) |
| Sep 29, 2021 | Jaime Vieser | Director | Buy | $191K (100,000 @ $1.91) |
| Sep 2, 2021 | Robert W Postma | Director | Buy | $94K (54,492 @ $1.73) |
| Sep 2, 2021 | Heidi Hagen | Director | Buy | $42K (23,770 @ $1.76) |
| Sep 2, 2021 | Robert W Postma | Director | Buy | $35K (20,508 @ $1.73) |
| Sep 1, 2021 | Holger Weis | Director | Buy | $92K (50,000 @ $1.83) |
| Sep 1, 2021 | James Huang | Director | Buy | $171K (100,000 @ $1.71) |
| Jan 8, 2021 | Kevin G Lafond | SVP, Treasurer & CAO | Sell | $56K (18,020 @ $3.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.